House Bill 743 Non-opioid Alternatives The bill revises these requirements for certain health care practitioners to inform patient or patient’s representative of nonopioid alternatives before prescribing or ordering an opioid drug by: • Requiring that the pamphlet provided to the patient be printed: the pamphlet can be downloaded at: http://www.floridahealth.gov/ programs-and-services/non-opioid-pain- management/_documents/alternatives-facts- 8.5x11-eng.pdf • Authorizing a health care practitioner to discuss non-opioid alternatives with, and provide the pamphlet to, the patient’s representative rather than the patient; • Removing the requirement to address non- opioid alternatives when a drug is dispensed or administered; and • Exempting hospice services and care provided in a hospital critical care unit or emergency department from the requirement to discuss non-opioid alternatives with a patient • Document the nonopioid alternatives considered in the patient’s record Conclusions All HCPs who treat pain with the use of opioids need up-to-date competencies to manage potential opioid-related harms. This includes a familiarity with the full complement of nonpharmacologic and pharmacologic options to create an individualized treatment plan, reserving opioids for when other strategies are not effective. An optimal multimodal approach to pain management consists of using treatments from one or more clinical disciplines incorporated into comprehensive plan. 1 For select patients who benefit from opioids long term, HCPs should reduce risk and optimize benefits by patient education, screening of high- risk patients for OUD, continuous monitoring, combining treatments with non-opioid options when indicated, referral and co-management of comorbid conditions, and an exit strategy to ensure careful tapering when indicated. It is important for patient outcomes and for regulatory and legal requirements to document every aspect of opioid therapy within the medical record and to follow all federal, state, and local regulations regarding opioid therapy. HCPs should know the signs and symptoms of OUD and be prepare to treat or refer for treatment with the understanding that medications for OUD are essential to save lives.
3.
Gereau RWIV, Sluka KA, Maixner W, et al. A Pain Research Agenda for the 21st Century. J Pain. 2014;15(12):1203- 1214. Hedegaard H, Warner M, Minino AM. Drug Overdose Deaths in the United States, 1999-2016. NCHS Data Brief. 2017(294):1-8. National Institute on Drug Abuse. Overdose Death Rates. https://www.drugabuse.gov/related-topics/trends- statistics/overdose-death-rates. Updated January 2021. Accessed July 30, 2021. Office of the Surgeon General. U.S. Surgeon General’s Advisory on Naloxone and Opioid Overdose. https://www. hhs.gov/surgeongeneral/priorities/opioids-and-addiction/ naloxone-advisory/index.html - ftn1. Published April 5, 2018. Accessed March 26, 2021. Centers for Disease Control and Prevention. Increase in Fatal Drug Overdoses Across the United States Driven by Synthetic Opioids Before and During the COVID-19 Pandemic. CDC Health Alert Network. https://emergency. cdc.gov/han/2020/han00438.asp. Published December 17, 2020. Accessed August 31, 2021. Florence CS, Zhou C, Luo F, Xu L. The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013. Med Care. 2016;54(10):901- 906.
18. Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63. Publication No. PEP20-02-01-006. Rockville, MD: Substance Abuse and Mental Health Services Administration. Published 2020. Accessed. 19. Chou R, Hartung D, Turner J, et al. Opioid Treatments for Chronic Pain. Comparative Effectiveness Review No. 229. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2015-00009-I.) AHRQ Publication No. 20-EHC011. Rockville, MD: Agency for Healthcare Research and Quality; April 2020. 20. Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain. 2017. 21. Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976-1982. 22. Tighe P, Buckenmaier CC, 3rd, Boezaart AP, et al. Acute Pain Medicine in the United States: A Status Report. Pain Med. 2015;16(9):1806-1826. 23. Scholz J, Finnerup NB, Attal N, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019;160(1):53-59. 24. Nicholas M, Vlaeyen JWS, Rief W, et al. The IASP classification of chronic pain for ICD-11: chronic primary pain. Pain. 2019;160(1):28-37. 25. Raffaeli W, Tenti M, Corraro A, et al. Chronic Pain: What Does It Mean? A Review on the Use of the Term Chronic Pain in Clinical Practice. J Pain Res. 2021;14:827-835. 26. American Medical Association. AMA urges CDC to revise opioid prescribing guideline [Press Release]. https://www. ama-assn.org/press-center/press-releases/ama-urges- cdc-revise-opioid-prescribing-guideline Published June 18, 2020. Accessed April 19, 2021. 27. Centers for Disease Control and Prevention. 2018 Annual Surveillance Report of Drug-Related Risks and Outcomes — United States. Surveillance Special Report. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. https://www.cdc.gov/ drugoverdose/pdf/pubs/2018-cdc-drug-surveillance- report.pdf. Published August 31, 2018. Accessed April 6, 2021. 28. U.S. Food and Drug Administration. Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS). https://www. fda.gov/drugs/information-drug-class/opioid-analgesic- risk-evaluation-and-mitigation-strategy-rems - top. Published September 27, 2018. Accessed. 29. Tick H, Nielsen A, Pelletier KR, et al. The Pain Task Force of the Academic Consortium for Integrative Medicine and Health. Evidence-based Nonpharmacologic Strategies for Comprehensive Pain Care. A Consortium Pain Task Force White Paper http://nonpharmpaincare.org/. Published December 15, 2017. Accessed 3-6-18. 30. Skelly AC CR, Dettori JR, et al. Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review. Comparative Effectiveness Review No. 209. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2015-00009- I.) AHRQ Publication No 18-EHC013-EF. Rockville, MD: Agency for Healthcare Research and Quality; June 2018. 31. Crawford C, Boyd C, Paat CF, et al. The Impact of Massage Therapy on Function in Pain Populations-A Systematic Review and Meta-Analysis of Randomized Controlled Trials: Part I, Patients Experiencing Pain in the General Population. Pain Med. 2016;17(7):1353-1375. 32. Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull. 2007;133(4):581-624.
4.
5.
6.
7.
8.
9. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569-576. 10. Muhuri PK, Gfroerer JC, Davies MC. Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States. https://www.samhsa.gov/data/sites/ default/files/DR006/DR006/nonmedical-pain-reliever- use-2013.htm. Published August 2013. Accessed May 12, 2021. 11. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71(7):821- 826. 12. Carlson RG, Nahhas RW, Martins SS, Daniulaityte R. Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study. Drug Alcohol Depend. 2016;160:127-134. 13. National Academies of Sciences Engineering and Medicine. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Washington, DC: The National Academies Press; 2017. 14. Institute of Medicine Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. In. Washington (DC): National Academies Press (US); 2011. 15. Dowell D, Haegerich T, Chou R. No Shortcuts to Safer Opioid Prescribing. N Engl J Med. 2019;380(24):2285- 2287. 16. U.S. Food and Drug Administration. FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering: FDA drug safety communication. https://www.fda.gov/drugs/drug- safety-and-availability/fda-identifies-harm-reported- sudden-discontinuation-opioid-pain-medicines-and- requires-label-changes Published April 9, 2019. Accessed August 17, 2021. 17. Kroenke K, Alford DP, Argoff C, et al. Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report. Pain Med. 2019;20(4):724-735.
References
1.
U.S. Department of Health and Human Services. Pain Management Best Practices Inter-Agency Task Force Report: Updates, Gaps, Inconsistencies, and Recommendations (Final Report). https://www.hhs.gov/ ash/advisory-committees/pain/index.html Published May 9, 2019. Accessed September 1, 2021. Nahin RL. Severe Pain in Veterans: The Effect of Age and Sex, and Comparisons With the General Population. J Pain. 2017;18(3):247-254.
2.
24
Powered by FlippingBook